Brain+

About Brain+

Brain+ is a health technology company that develops digital therapies to support cognitive rehabilitation and mental health. The company's solutions combine neuroscience, technology and game design to help people with neurological diseases such as Alzheimer's and other cognitive impairments. Brain+ works with healthcare providers and research institutions to integrate its products into clinical settings. The company was founded in 2012 and is headquartered in Copenhagen.

Kategori

All

Analysis monitoring

Finvoices

Hot Chair

Report comment

2025-09-24

Brain+ Coverage Commentary - Launches first NHS pilot in UK primary care

Impala Nordic comments the news that Brain+ has signed an agreement to deploy the Company’s Cognitive Stimulation Therapy (“CST”) Assistant, Ayla, in one of the UK’s largest primary care practices within the UK National Health Service (“NHS”). We view this agreement as a landmark step for Ayla’s UK adoption.

2025-09-03

Brain+ - Strategy on track, revenue defers into 2026

Impala Nordic comments on the half-year report for H1 2025. The report is broadly in line with expectations, showing continued progress in UK private care homes. The company maintains its target of operational cash-flow break-even by mid-2026 and expects to achieve at least DKK 3.6m in contracted sales.

However, the expected realized cash flow from sales in 2025 has been adjusted to DKK 3.0m due to longer cycles from contracting to invoicing. On 2 September 2025, Brain+ expanded its agreement with Southcare to include three additional homes, further strengthening scalability in the UK, which we consider central to the investment case.

2025-06-25

Impala Nordic publishes equity analysis on Brain+ A/S

Impala Nordic initiates coverage on Brain+, a Danish life-science company pioneering digital solutions for improved dementia care, helping people affected by dementia live better lives.

The Company is developing Ayla, the world’s first dementia-care platform, aiming to reach operational break-even by mid 2026.

2025-05-27

FinVoices: Devika Wood, CEO at Brain+ A/S

In this episode, Brain+’s newly appointed CEO Devika Woods shares her background in digital health and her vision for the company’s potential.

She explains how the Ayla platform delivers Cognitive Stimulation Therapy to improve memory and attention, and discusses the UK healthcare system and efforts to integrate Brain+’s CST solution.

Listen to podcast episodes

2025-03-26

Impala Nordic initiates analysis coverage on Brain+ A/S and initiates with a teaser.

Brain+ is a Danish health tech company transforming dementia care by enabling scalable, high-quality solutions for health and care providers.

The Company is developing Ayla, the world’s first dementia care platform for the scalable delivery of Cognitive Stimulation Therapy (CST), the leading non-pharmacological therapy for dementia.

Read analysis coverage

2025-03-17

Hot Chair - Brain+

We have interviewed Kim Baden-Kristensen, CEO of Brain+. Kim shares insights into the company’s operations, strategy, and future outlook.

He also provides his perspective on the digital healthcare market and the key factors investors should keep an eye on in the coming years.

Read interview